Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Escalating venetoclax dose was safe in relapsed CLL

Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

Key clinical point: Quick ramp up of venetoclax dosing in relapsed CLL appears safe.

Major finding: All patients reached the target dose of venetoclax, with only two cases of manageable clinical tumor lysis syndrome.

Study details: Retrospective analysis of outcomes for 15 patients with CLL who relapsed after treatment with a B-cell receptor signaling inhibitor.

Disclosures: The study was internally funded. Dr. Awan reported research funding from Gilead, Pharmacyclics, AbbVie, and Janssen.

Source: Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

Read the article.

Citation:

Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

This Week's Must Reads

Must Reads in Aggressive Lymphomas

Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NHL, Advani R et al. N Engl J Med. 2018;379:1711-21

Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025

Complications in EPOCH-R versus R-CHOP, David RJ et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 29. doi: 10.1016/j.clml.2018.08.014